Synergy Pharmaceuticals (SGYP) touted Trulance as an alternative to Ironwood's Linzess for chronic idiopathic constipation (CIC), which was known to cause diarrhea and could limit its real-world use. Synergy's bid to improve upon Linzess helped shares peak at a $1.4 billion valuation in early 2017 (as shown in Figure 1, below).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.